Publications by authors named "M-J Asensio"
Article Synopsis
- The study investigates the long-term outcomes of patients with metastatic renal cell carcinoma who achieved a complete response to the TKI sunitinib, revealing little known prior information about this group.
- Data was collected from a registry of 62 patients treated in Spain between 2007 and 2018, with most patients having clear cell histology and previously undergoing nephrectomy.
- Results show that 75% of patients maintained complete response status after 10 years, indicating durable responses across different prognosis groups and metastasis sites.
Conventionally, hyperimmune globulin drugs manufactured from pooled immunoglobulins from vaccinated or convalescent donors have been used in treating infections where no treatment is available. This is especially important where multi-epitope neutralization is required to prevent the development of immune-evading viral mutants that can emerge upon treatment with monoclonal antibodies. Using microfluidics, flow sorting, and a targeted integration cell line, a first-in-class recombinant hyperimmune globulin therapeutic against SARS-CoV-2 (GIGA-2050) was generated.
View Article and Find Full Text PDFTo discover therapeutically relevant antibody candidates, many groups use mouse immunization followed by hybridoma generation or B cell screening. One modern approach is to screen B cells by generating natively paired single chain variable fragment (scFv) display libraries in yeast. Such methods typically rely on soluble antigens for scFv library screening.
View Article and Find Full Text PDF